Risk minimization measures in pharmacovigilance: review of national and international experience
https://doi.org/10.24411/2588-0519-2019-10081
Abstract
The use of risk-based approach in pharmacovigilance management is due to the strategy of preventive measures to ensure the safe administration of medicines. Now, manufacturers of drugs to ensure the functions of pharmacovigilance provide a set of documents registering the safety of products, including a risk management plan. In the process of preparing a risk management plan, risks are identified and assessed, measures to minimize them are developed and the effectiveness of these measures is further evaluated. The article considers risk factors in relation to pharmacovigilance for a drug and examples of their occurrence. Routine and additional measures to minimize risks are used to ensure risk management. In the case of biotechnological drugs, it is not superfluous to conduct post-registration studies with pharmacoepidemiological design with mandatory publication of both positive and negative results. The article analyzes the domestic and foreign experience of measures to minimize risks. If a particular strategy is found to be ineffective, alternative interventions should be developed and implemented. A possible result of ineffective risk minimization measures is the withdrawal of drugs from the market or the restriction of their use only to the subgroup of patients for whom the benefits outweigh the risks. Manufacturers should not neglect the implementation of measures to minimize risks, as this prevents the application of drastic measures of regulatory authorities in relation to them and allows the drug to exist on the market in a safe application, providing quality medical care for patients.
About the Author
V. A. Komissarova
Yaroslavl State Medical University
Russian Federation
Russian Federation
Komissarova Victoria - Postgraduate Student, Department of Clinical Pharmacology
Yaroslavl
References
1. Reshenie Soveta Evraziiskoi ekonomicheskoi komissii №87 «Ob utverzhdenii Pravil nadlezhashchei praktiki farmakonadzora Evraziiskogo ekonomicheskogo soyuza» ot 03.11.2016 (In Russ). URL: http://www.consultant.ru/document/cons_doc_LAW_207352/. (дата обращения: 20.10.2019).
2. Titova AR, Asetskaya IL, Zyryanov SK, Polivanov VA. Nereglamentirovannoe (off-label) primenenie lekarstvennykh preparatov v pediatricheskoi praktike: nereshennye problemy. Pediatricheskaya farmakologiya. 2015;12(3):304-308. (In Russ). DOI: 10.15690/pf.v12i3.1355
3. Popova NS, Filippova AV, Galankin TL, et al. Gepatotoksichnost’ novykh oral’nykh antikoagulyantov: obzor literatury. Kachestvennaya klinicheskaya praktika. 2018;3:66-72. (In Russ). DOI: 10.24411/2588-0519-2018-10052
4. Vel’ts NYu, Bukatina TM, Zhuravleva EO, Kutekhova GV, Darmostukova MA, Olefir YuV, Romanov BK, Glagolev SV, Polivanov VA. K voprosu o bezopasnosti primeneniya nesteroidnykh protivovospalitel’nykh preparatov. Bezopasnost’ i risk farmakoterapii. 2018;6(3):123-129. (In Russ). DOI: 10.30895/2312-7821-2018-6-3-123-129
5. Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate [online]. URL: https://www.takeda.com/newsroom/newsreleases/2019/takeda-issues-us-recall-of-natpara-parathyroid-hormone-for-injection-due-to-the-potential-for-rubber-particulate/ (дата обращения: 20.10.2019).
6. Takeda soobshchaet ob otzyve preparata NATPARA® v SShA. Novosti GMP. (In Russ). URL: https://gmpnews.ru/2019/09/takeda-soobshhaet-ob-otzyve-preparata-natpara-v-ssha/ (дата обращения: 20.10.2019).
7. FDA Drug Safety Communication: Medication errors resulting from confusion between risperidone (Risperdal) and ropinirole (Requip) [online]. URL: http://www.fda.gov/Drugs/DrugSafety/ucm258805.htm (дата обращения: 20.10.2019).
8. Kuz’mina AV, Asetskaya IL, Polivanov VA, Zyryanov SK. Meditsinskie oshibki pri primenenii lekarstvennykh preparatov v prakticheskom zdravookhranenii. Prakticheskaya pul’monologiya. 2016;3:7683. (In Russ). URL: https://cyberleninka.ru/article/n/meditsinskie-oshibki-pri-primenenii-lekarstvennyh-preparatov-v-prakticheskom-zdravoohranenii (дата обращения: 20.10.2019).
9. Vosstanavlivayutsya sertifikaty prigodnosti na substantsiyu valsartan s uchetom kontrolya NDMA. Novosti GMP. (In Russ). URL: https://gmpnews.ru/2019/06/vosstanavlivayutsya-sertifikaty-prigodnosti-na-substanciyu-valsartan-s-uchetom-kontrolya-ndma/ (дата обращения: 20.10.2019).
10. Informatsionnoe pis’mo Federal’noi sluzhby po nadzoru v sfere zdravookhraneniya (Roszdravnadzor) ot 17.06.2019. O vosstanovlenii sertifikata prigodnosti na substantsiyu «Valsartan». (In Russ). URL: http://www.roszdravnadzor.ru/i/upload/images/2019/6/18/1560849139.45713-1-14261.pdf (дата обращения: 20.10.2019).
11. Informatsionnoe pis’mo Federal’noi sluzhby po nadzoru v sfere zdravookhraneniya (Roszdravnadzor) ot 17.06.2019. O vosstanovlenii sertifikata prigodnosti na substantsiyu «Valsartan». (In Russ). URL: http://www.roszdravnadzor.ru/i/upload/images/2019/6/18/1560848834.95545-1-31903. pdf (дата обращения: 20.10.2019).
12. FDA: v obraztsakh ranitidina obnaruzheny primesi nitrozamina. Novosti GMP. (In Russ). URL: https://gmpnews.ru/2019/09/fda-v-obrazcax-ranitidina-obnaruzheny-primesi-nitrozamina/ (дата обращения: 20.10.2019)
13. Statement alerting patients and health care professionals of NDMA found in samples of ranitidine [online]. URL: https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine (дата обращения: 20.10.2019).
14. Roszdravnadzor prokommentiroval situatsiyu s vyyavleniem primesi NDMA v ranitidine. Novosti GMP. (In Russ). URL: https://gmpnews.ru/2019/10/roszdravnadzor-prokommentiroval-situaciyu-s-vyyavleniem-primesi-ndma-v-ranitidine/ (дата обращения: 20.10.2019).
15. Asetskaya IL, Zyryanov SK, Kolbin AS, Belousov DYu. Sistema farmakonadzora v Evraziiskom ekonomicheskom soyuze. Kachestvennaya klinicheskaya praktika. 2018;4:53-72. (In Russ). DOI: 10.24411/2588-0519-2018-10059
16. Makhmutova N.M. Upravlenie riskami kak element sistemy farmakonadzora. Obrazovanie i nauka v sovremennykh realiyakh: materialy IV Mezhdunar. nauch.—prakt. konf. 2018;25-27. (In Russ).
17. Reshenie Soveta Evraziiskoi ekonomicheskoi komissii №88 «Ob utverzhdenii trebovanii k instruktsii po meditsinskomu primeneniyu lekarstvennykh preparatov i obshchei kharakteristike lekarstvennykh preparatov dlya meditsinskogo primeneniya» ot 03.11.2016 (In Russ). URL: https://pharmvestnik.ru/documents/reshenie-soveta-evrazijskoj-ekonomicheskoj-komissii-88-ot-03-11-2016-g.html (дата обращения: 20.10.2019).
18. ANSM: na upakovkakh s paratsetamolom dolzhna poyavit’sya preduprezhdayushchaya nadpis’. Novosti GMP. (In Russ). URL: https://gmpnews.ru/2019/07/ansm-na-upakovkax-s-paracetamolom-dolzhna-poyavitsya-preduprezhdayushhaya-nadpis/ (дата обращения: 20.10.2019).
19. Paracétamol et risque pour le foie: un message d’alerte ajouté sur les boîtes de médicament – Communiqué [online]. URL: https://www.ansm.sante.fr/S-informer/Communiques-Communiques-Points-presse/Paracetamol-et-risque-pour-le-foie-un-message-d-alerte-ajoute-sur-les-boites-de-medicament-Communique (дата обращения: 20.10.2019).
20. Informatsionnoe pis’mo Federal’noi sluzhby po nadzoru v sfere zdravookhraneniya (Roszdravnadzor) ot 29.10.2019. O novykh dannykh po bezopasnosti lekarstvennogo preparata Implanon NKST®. (In Russ). URL: http://roszdravnadzor.ru/i/upload/images/2019/10/30/1572459701.78951-1-455.pdf (дата обращения: 30.10.2019).
21. 4 klyuchevykh parametra dlya sozdaniya ideal’noi upakovki lekarstva. Novosti GMP. (In Russ). URL: https://gmpnews.ru/2018/11/4-klyuchevyx-parametra-dlya-sozdaniya-idealnoj-upakovki-lekarstva/(дата обращения: 20.10.2019).
22. FDA vvelo ogranicheniya na razmer upakovki dlya loperamida. Novosti GMP. (In Russ). URL: https://gmpnews.ru/2019/09/fda-vvelo-ogranicheniya-na-razmer-upakovki-dlya-loperamida/ (дата обращения: 20.10.2019).
23. FDA limits packaging for anti-diarrhea medicine loperamide (Imodium) to encourage safe use [online]. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-limits-packaging-anti-diarrhea-medicine-loperamide-imodium-encourage-safe-use (дата обращения: 20.10.2019).
24. Uzhestochaetsya nakazanie za narusheniya pri oborote tropikamida, tapentadola i pregabalina. Novosti GMP. (In Russ). URL: https://gmpnews.ru/2019/06/s-1-dekabrya-2019-g-uzhestochaetsya-nakazanie-za-narusheniya-pri-oborote-tropikamida-tapentadola-i-pregabalina/ (дата обращения: 20.10.2019).
25. V novyi perechen’ retsepturnykh lekarstv Belarusi vnesut sushchestvennye izmeneniya. Novosti GMP. (In Russ). URL: https://gmpnews.ru/2019/04/v-novyj-perechen-recepturnyx-lekarstv-belarusi-vnesut-sushhestvennye-izmeneniya/ (дата обращения: 20.10.2019).
26. V SShA izmenyat pravila naznacheniya opioidov s bystrym vysvobozhdeniem. Novosti GMP. (In Russ). URL: https://gmpnews.ru/2017/07/v-ssha-izmenyat-pravila-naznacheniya-opioidov-s-bystrym-vysvobozhdeniem/ (дата обращения: 20.10.2019).
27. Informatsionnoe pis’mo Federal’noi sluzhby po nadzoru v sfere zdravookhraneniya (Roszdravnadzor) ot 30.08.2019. O novykh dannykh po bezopasnosti lekarstvennogo preparata Ksarelto (In Russ). URL: http://roszdravnadzor.ru/i/upload/images/2019/8/30/1567177535.6747-1-25030.pdf (дата обращения: 30.10.2019).
28. Informatsionnoe pis’mo Federal’noi sluzhby po nadzoru v sfere zdravookhraneniya (Roszdravnadzor) ot 15.08.2019. O novykh dannykh po bezopasnosti lekarstvennogo preparata Adenurik. (In Russ). URL: http://roszdravnadzor.ru/i/upload/images/2019/8/15/1565885843.39686-1-29560.pdf (дата обращения: 30.10.2019)..
29. Informatsionnoe pis’mo Federal’noi sluzhby po nadzoru v sfere zdravookhraneniya (Roszdravnadzor) ot 16.07.2019. O novykh dannykh po bezopasnosti lekarstvennogo preparata Lemtrada® (MNN — alemtuzumab). (In Russ). URL: http://roszdravnadzor.ru/i/upload/images/2019/7/16/1563287387.16882-1-22609.pdf (дата обращения: 30.10.2019).
30. Informatsionnoe pis’mo Federal’noi sluzhby po nadzoru v sfere zdravookhraneniya (Roszdravnadzor) ot 24.10.2019. O bezopasnom primenenii lekarstvennogo preparata Metotreksat-Ebeve. (In Russ). URL: http://roszdravnadzor.ru/i/upload/images/2019/10/24/1571946957.51954-1-17783.pdf (дата обращения: 30.10.2019).
31. Starodubov VI, Kagramanyan IN, Khokhlov AL, et al. Оtsenka meditsinskikh tekhnologii. Mezhdunarodnyi opyt./ Pod red. V.I. Starodubova, I.N. Kagramanyana. Moskva: 2012. (In Russ).
32. Farmakonadzor / Pod red. Kolbina AS, Zyryanova SK, Belousova DYu. Moscow: Izdatel’stvo OKI:Buki Vedi; 2019. (In Russ).
33. Biologicheskie preparaty. Terapevticheskie monoklonal’nye antitela s pozitsii klinicheskoi farmakologii / Pod red. Kolbina AS. — SPb: TsOP «Professiya», 2019. (In Russ).
34. Rakov AA, Khokhlov AL, Fedorov VN, et al. Farmakoepidemiologiya khronicheskoi serdechnoi nedostatochnosti u ambulatornykh bol’nykh. Kachestvennaya klinicheskaya praktika. 2003;2:40-43. (In Russ).
35. Khokhlov AL, Lisenkova LA. Farmakoepidemiologicheskoe issledovanie antigipertenzivnoi terapii v pozhilom vozraste. Klinicheskaya gerontologiya. 2003;9(7):31-34. (In Russ).
36. Levy R, Pillai L, Burnett B, et al. Efficacy and safety of flavocoxid compared with naproxen in subjects with osteoarthritis of the knee — a subset analysis. Advances in Therapy. 2010;27(12):953-962.
37. Lileeva EG, Khokhlov AL. Farmakoepidemiologicheskoe issledovanie lecheniya i profilaktiki gipertonicheskikh krizov na dogospital’nom etape. Kachestvennaya klinicheskaya praktika. 2006;1:46-50. (In Russ).
38. Who’s not sharing their trial results? // The Trials Tracker [online]. URL: https://trialstracker.ebmdatalab.net/#/ (дата обращения 31.10.2019)
39. Belyalov FI. Eff ektivnost’ i bezopasnost’ lekarstv: rol’ farmatsevticheskoi industrii. Ratsional’naya farmakoterapiya v kardiologii. 2015;11(4):420-425. (In Russ).
40. Cheprakova VA, Kurasov ES. Eticheskie printsipy v sovremennykh klinicheskikh issledovaniyakh: effektivnaya pomoshch’ ili ochevidnoe prepyatstvie? Vestnik rossiiskoi voenno-meditsinskoi akademii. 2015;3(5):158-161. (In Russ).
41. William E. Boden, Robert A. O’Rourke, Koon K. Teo, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. The New England Journal of Medicine. 2007;356:1503-1516. DOI: 10.1056/NEJMoa070829
Review
For citations:
Komissarova V.A. Risk minimization measures in pharmacovigilance: review of national and international experience. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2019;(3):33-43. (In Russ.) https://doi.org/10.24411/2588-0519-2019-10081
Views:
1889
Email this article 